CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis
19/04/2018 – AB Science will provide additional data through a reexamination procedure
19/04/2018 – AB Science will provide additional data through a reexamination procedure
04/01/2018 – Additionally, the IDMC did not report any safety concern with masitinib in the study population.